Long non‑coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR‑675

Xu, Yongzi; Liu, Qing; Li, Zhenrong; Li, Hao; Li, Xiqing; Liang, Yan; Mao, Jian; Shen, Jian; Chen, Wei

doi:10.3892/or.2020.7608

Cited by 37 publications

(24 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, many drugs for HCC still have toxic side effects, which limit their usage in the clinic ( Cheung et al., 2007 ; Sak, 2012 ; Chen et al., 2020 ; Zingales et al., 2020 ), and drug resistance of HCC hampers the treatment effects ( Xiong et al. ; Folmer et al., 2007 ; Tan et al., 2019 ; Li et al., 2020 ; Xu et al., 2020 ; Yang et al., 2020 ). Hence, it is urgent to discover new curative compounds with less adverse effects to treat this disease.…”

Section: Introductionmentioning

confidence: 99%

An Integrative Serum Pharmacology-Based Approach to Study the Anti-Tumor Activity of B. paniculatum Aqueous Bulb Extract on the Human Hepatocellular Carcinoma Cell Line BEL-7404

Feng

Shi

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

The herb Bolbostemma paniculatum (Maxim) Franquet (Cucurbitaceae family), also known as Tu-Bei-Mu (TBM) in Chinese, has shown curative effects to treat several types of cancer as an adjunctive therapy. Thereby we intend to find its effect on the human hepatocellular carcinoma (HCC) and to understand the pharmacological mechanism behind it. In this study, an integrative serum pharmacology-based approach linking serum pharmacology and bioinformatics prediction was employed. Firstly, we used the serum taken introgastrically from the rats dministered by TBM aqueous bulb extract to culture the HCC cell line BEL-7404 and detect its anti-tumor effects. Secondly, the TBM putative targets were predicted using the ETCM database and known therapeutic targets of NPC were collected from the OMIM database. Then, a TBM-HCC putative targets network was constructed using the DAVID and STRING databases. Thirdly, key gene targets were obtained based on topological analysis and pathway enrichment analysis. The expression of 4 representative key targets were validated by Western blotting. As a result, 36 TBM targets and 26 known therapeutic targets of HCC were identified. These key targets were found to be frequently involved in 13 KEGG pathways and 4 biological processes. The expression of four representative key targets: TP53, CASP3, BCL2 and BAX further supports the suppression of TBM on HCC. In general, our study shows the curative effects of TBM against HCC. By using this integrative approach, we may find novel potential therapeutic targets to suppress HCC using TBM as an adjunctive therapy. And it could also help us understand the mechanism of HCC treatments in response to TBM.

show abstract

Section: Introductionmentioning

confidence: 99%

An Integrative Serum Pharmacology-Based Approach to Study the Anti-Tumor Activity of B. paniculatum Aqueous Bulb Extract on the Human Hepatocellular Carcinoma Cell Line BEL-7404

Feng

Shi

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In the latest study on the relationship of H19 with sorafenib resistance, H19 expression in HCC tissue samples was significantly upregulated compared with normal tissues. Knockdown of H19 sensitized HCC cells to sorafenib by downregulating miR-675 and suppressing EMT (Xu et al 2020 ). However, the role of H19 in therapy resistance of HCC is not completely elucidated.…”

Section: Introductionmentioning

confidence: 99%

Role of long non-coding RNA H19 in therapy resistance of digestive system cancers

Wang

et al. 2021

Mol Med

View full text Add to dashboard Cite

Digestive system cancers are associated with high morbidity and mortality. Chemotherapy and radiotherapy are the main treatment modalities for these cancers. However, the development of therapy resistance leads to high rates of tumor recurrence and metastasis, resulting in dismal prognosis. Long non-coding RNA (LncRNA) H19, one of the most intriguing non-coding RNAs, has been shown to play a key role in the development and therapy resistance of various digestive system cancers (including hepatocellular carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, esophageal carcinoma, gastric cancer, and biliary system cancer) by regulating the abnormal expression of genes. In this review, we discuss the potential mechanisms of LncRNA H19 related therapy resistance in the context of digestive system cancers. LncRNA H19 is a potential novel therapeutic target for amelioration of cancer therapy resistance.

show abstract

“…Inhibition of lncRNA H19 could increase the sensitivity of sorafenib by inhibiting the epithelial-mesenchymal transition (EMT) of HCC cells. 18 Wu et al proved that the up-regulation of lncRNA FTX inhibited the conversion of non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma by promoting M1 polarization of Kupffer cells. 19 Therefore, lncRNAs can be used as novel prognostic markers and potential therapeutic targets for HCC.…”

Section: Introductionmentioning

confidence: 99%

Long Non-Coding RNA TRIM52-AS1 Promotes Growth and Metastasis via miR-218-5p/ROBO1 in Hepatocellular Carcinoma

Liu

et al. 2021

CMAR

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is a malignant disease with a high mortality among primary HCC patients worldwide. Lots of studies have shown that lncRNAs are known as the biomarkers in diagnosis, treatment and prognosis of hepatocellular carcinoma. Therefore, clarifying the detailed function and mechanism of the lncRNA in the HCC progressing seems particularly important. Methods: The TCGA and GEO database and RT-qPCR were used to analyse the expression of TRIM52-AS1 in HCC tissues and cell lines. Clinical data were collected to further analyze the correlation between indicators of clinical samples and the expression of TRIM52-AS1. CCK-8, plate clone and transwell assays were employed to evaluate the role of TRIM52-AS1 on cell proliferation, migration and invasion. Then, bioinformatics prediction, luciferase reporter, RNA immunoprecipitation (RIP), and RT-qPCR were employed to analyze the direct interaction among TRIM52-AS1, miR-218-5p and ROBO1. Additionally, the rescue function assays were used to verify that miR-218-5p/ROBO1 was the function downstream of TRIM52-AS1. Results: TRIM52-AS1 was overexpressed in HCC according to the TCGA database and RT-qPCR assay. The expression of TRIM52-AS1 was higher in the metastatic foci compared with primary tumor according to the GEO database. Additionally, TRIM52-AS1 knockdown inhibited the proliferation and metastasis of HCC cells. TRIM52-AS1 could act as competitive endogenous RNA to regulate ROBO1 through miR-218-5p, then promoted the HCC cell progression. Conclusion: TRIM52-AS1 is overexpressed in HCC and can promote the proliferation and metastasis of HCC cells through miR-218-5p/ROBO1 axis, then drives the HCC cell progression.

show abstract

Long non‑coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR‑675

Cited by 37 publications

References 31 publications

An Integrative Serum Pharmacology-Based Approach to Study the Anti-Tumor Activity of B. paniculatum Aqueous Bulb Extract on the Human Hepatocellular Carcinoma Cell Line BEL-7404

An Integrative Serum Pharmacology-Based Approach to Study the Anti-Tumor Activity of B. paniculatum Aqueous Bulb Extract on the Human Hepatocellular Carcinoma Cell Line BEL-7404

Role of long non-coding RNA H19 in therapy resistance of digestive system cancers

Long Non-Coding RNA TRIM52-AS1 Promotes Growth and Metastasis via miR-218-5p/ROBO1 in Hepatocellular Carcinoma

Contact Info

Product

Resources

About